October 19, 2023 Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission Inside information, Regulated EN NL
October 18, 2023 Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome Inside information, Regulated EN NL
October 6, 2023 Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 November 2023 Regulated EN NL
October 4, 2023 SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Regulated EN NL
September 14, 2023 Sequana Medical announces H1 2023 results and provides business update Inside information, Regulated EN NL
September 6, 2023 Sequana Medical Notice of 2023 Half-year Results and Business Update Non-regulated EN NL
July 10, 2023 Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure Non-regulated EN NL
June 26, 2023 Sequana Medical announces results of Special General Meeting of Shareholders Regulated EN NL
June 21, 2023 Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON) Inside information, Regulated EN NL